Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $13 from $17 and keeps a Buy rating on the shares. Management guided that preliminary proof-of-concept efficacy results from the ongoing global Phase 1/2 study of ENTR-601-44 and ENTR-601-45 are expected in 2Q26 and mid-2026, respectively, the analyst tells investors in a research note. While the firm remains enthusiastic about the company’s pipeline programs, it lowered its price target on the shares to reflect the broader market sentiment and advances made by competing agents.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform
- Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.
- Entrada Therapeutics files $400M mixed securities shelf
- Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
- Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline